Hippocampal Glycerol-3-Phosphate Acyltransferases 4 and BDNF in the Progress of Obesity-Induced Depression.
AMP-Activated Protein Kinases
/ genetics
Animals
Behavior, Animal
Brain-Derived Neurotrophic Factor
/ genetics
Cyclic AMP Response Element-Binding Protein
/ genetics
Depression
/ etiology
Diet, High-Fat
Glycerol-3-Phosphate O-Acyltransferase
/ genetics
Hippocampus
/ metabolism
Male
Mice
Mice, Inbred C57BL
Obesity
/ complications
Swimming
Weight Gain
depression
glycerol-3-phosphate acyltransferases 4
high fat diet
hippocampus
inflammation
ventromedical hypothalamus
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
02
2021
accepted:
19
04
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Obesity has been reported to lead to increased incidence of depression. Glycerol-3-phosphate acyltransferases 4 (GPAT4) is involved in triacylglycerol synthesis and plays an important role in the occurrence of obesity. GPAT4 is the only one of GPAT family expressed in the brain. The aim of this study is to investigate if central GPAT4 is associated with obesity-related depression and its underlying mechanism. A high-fat diet resulted in increased body weight and blood lipid. HFD induced depression like behavior in the force swimming test, tail suspension test and sucrose preference test. HFD significantly up-regulated the expression of GPAT4 in hippocampus, IL-1β, IL-6, TNF-α and NF-κB, accompanied with down-regulation of BDNF expression in hippocampus and ventromedical hypothalamus, which was attributed to AMP-activated protein kinase (AMPK) and cAMP-response element binding protein (CREB). Our findings suggest that hippocampal GPAT4 may participate in HFD induced depression through AMPK/CREB/BDNF pathway, which provides insights into a clinical target for obesity-associated depression intervention.
Sections du résumé
Background
Obesity has been reported to lead to increased incidence of depression. Glycerol-3-phosphate acyltransferases 4 (GPAT4) is involved in triacylglycerol synthesis and plays an important role in the occurrence of obesity. GPAT4 is the only one of GPAT family expressed in the brain. The aim of this study is to investigate if central GPAT4 is associated with obesity-related depression and its underlying mechanism.
Results
A high-fat diet resulted in increased body weight and blood lipid. HFD induced depression like behavior in the force swimming test, tail suspension test and sucrose preference test. HFD significantly up-regulated the expression of GPAT4 in hippocampus, IL-1β, IL-6, TNF-α and NF-κB, accompanied with down-regulation of BDNF expression in hippocampus and ventromedical hypothalamus, which was attributed to AMP-activated protein kinase (AMPK) and cAMP-response element binding protein (CREB).
Conclusion
Our findings suggest that hippocampal GPAT4 may participate in HFD induced depression through AMPK/CREB/BDNF pathway, which provides insights into a clinical target for obesity-associated depression intervention.
Identifiants
pubmed: 34054732
doi: 10.3389/fendo.2021.667773
pmc: PMC8158158
doi:
Substances chimiques
Bdnf protein, mouse
0
Brain-Derived Neurotrophic Factor
0
Cyclic AMP Response Element-Binding Protein
0
GPAT4 protein, mouse
EC 2.3.1.15
Glycerol-3-Phosphate O-Acyltransferase
EC 2.3.1.15
AMP-Activated Protein Kinases
EC 2.7.11.31
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
667773Informations de copyright
Copyright © 2021 Huang, Wang, Hu, Lin and Lin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pharmacol Biochem Behav. 2004 Jun;78(2):269-74
pubmed: 15219767
Behav Res Ther. 2011 Dec;49(12):821-9
pubmed: 22005587
Mol Psychiatry. 2014 Jul;19(7):791-800
pubmed: 23958957
J Neuroimmunol. 2010 Feb 26;219(1-2):25-32
pubmed: 20004026
J Neurosci. 1995 Nov;15(11):7539-47
pubmed: 7472505
Front Mol Neurosci. 2019 Dec 11;12:298
pubmed: 31920532
Front Neurosci. 2019 Dec 20;13:1340
pubmed: 31920505
Nutr Metab Cardiovasc Dis. 2007 Jun;17(5):358-64
pubmed: 16928439
Nat Rev Endocrinol. 2016 Jul;12(7):421-32
pubmed: 27199291
JAMA Psychiatry. 2013 Jan;70(1):31-41
pubmed: 22945416
J Neuroimmunol. 2008 Aug 30;200(1-2):90-9
pubmed: 18653240
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
J Neurosci Res. 2006 Mar;83(4):557-66
pubmed: 16429444
Obes Rev. 2014 Jan;15(1):29-39
pubmed: 24034448
Mol Psychiatry. 2008 Jul;13(7):717-28
pubmed: 17700577
Mol Neurobiol. 2018 May;55(5):4195-4206
pubmed: 28612257
J Neurosci. 2014 Feb 12;34(7):2618-31
pubmed: 24523551
Neurosci Lett. 2007 Sep 7;424(2):106-10
pubmed: 17716817
J Biol Chem. 2008 Apr 11;283(15):10048-57
pubmed: 18238778
Eur Heart J. 2017 May 7;38(18):1436-1438
pubmed: 26715164
Nat Neurosci. 2007 Sep;10(9):1089-93
pubmed: 17726474
Mol Neurodegener. 2016 Jul 12;11(1):51
pubmed: 27406263
Psychosom Med. 2009 Feb;71(2):171-86
pubmed: 19188531
Transl Psychiatry. 2019 May 10;9(1):141
pubmed: 31076569
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11024-31
pubmed: 11572963
Mol Psychiatry. 2012 Sep;17(9):940-5
pubmed: 22525487
Neurology. 2010 May 18;74(20):1643-50
pubmed: 20479364
Neurobiol Aging. 2008 Sep;29(9):1380-93
pubmed: 17467122
J Affect Disord. 2013 Sep 25;150(3):736-44
pubmed: 23870425
J Neurosci. 2002 Apr 15;22(8):3251-61
pubmed: 11943826
Biol Psychiatry. 2012 Jan 1;71(1):15-21
pubmed: 22047718
J Lipid Res. 2010 Jul;51(7):1971-81
pubmed: 20181984
J Pharmacol Sci. 2003 Apr;91(4):267-70
pubmed: 12719654
J Lipid Res. 2006 Apr;47(4):745-54
pubmed: 16436371
Neuroimmunomodulation. 2020;27(2):87-96
pubmed: 33176302
Br J Nutr. 2013 Nov;110(10):1856-65
pubmed: 23668671
Neuroscience. 2013 Jun 3;239:196-213
pubmed: 22967840
Brain Behav Immun. 2010 Feb;24(2):243-53
pubmed: 19825412
Curr Neurovasc Res. 2020;17(2):196-203
pubmed: 32189593
PLoS One. 2011;6(9):e24325
pubmed: 21949705
Biol Psychiatry. 2008 Sep 15;64(6):484-90
pubmed: 18514163
Mol Psychiatry. 2019 Jan;24(1):18-33
pubmed: 29453413
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):251-62
pubmed: 22436748
Science. 2015 Jun 26;348(6242):1472-7
pubmed: 26113723
Int J Obes Relat Metab Disord. 2004 Jun;28(6):790-5
pubmed: 15024401
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1500-5
pubmed: 9037082
Endocrine. 2017 Apr;56(1):65-72
pubmed: 27981512
Biol Psychiatry. 2010 Mar 1;67(5):446-57
pubmed: 20015486
J Clin Psychiatry. 2005 Aug;66(8):1002-11
pubmed: 16086615
Am J Physiol Endocrinol Metab. 2009 Jun;296(6):E1195-209
pubmed: 19336658
Science. 2003 Dec 5;302(5651):1760-5
pubmed: 14615545
Nat Commun. 2020 Dec 10;11(1):6326
pubmed: 33303759
Int J Obes (Lond). 2013 Nov;37(11):1427-34
pubmed: 23459323
Front Neurosci. 2013 Mar 21;7:37
pubmed: 23519010
Pharmacol Ther. 2011 May;130(2):226-38
pubmed: 21334376
Nutr Diabetes. 2018 May 25;8(1):34
pubmed: 29799006
Am J Physiol Endocrinol Metab. 2014 Aug 1;307(3):E305-15
pubmed: 24939733
Physiol Behav. 1996 Dec;60(6):1481-4
pubmed: 8946494
Psychol Med. 2012 Oct;42(10):2015-26
pubmed: 22336436
J Neuroimmunol. 2004 Oct;155(1-2):119-26
pubmed: 15342202
Eur J Neurosci. 2021 Mar 12;:
pubmed: 33711185
JAMA Psychiatry. 2014 Dec 1;71(12):1381-91
pubmed: 25322082
Endocr Rev. 2002 Apr;23(2):201-29
pubmed: 11943743
Arch Gen Psychiatry. 2006 Jul;63(7):824-30
pubmed: 16818872